Enanta Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
February 01 2016 - 8:00AM
Business Wire
Presentation to be Webcast on February 10,
2016 at 9:15 A.M. ET
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that Jay R. Luly, Ph.D., President and Chief Executive
Officer, will participate in a fireside chat format, or question
and answer session with investors, at the LEERINK Partners 5th
Annual Global Healthcare Conference on February 10, 2016 at 9:15
a.m. ET.
A live webcast and replay of the presentation will be accessible
by visiting the “Calendar of Events” section on the “Investors”
page of Enanta’s website at www.enanta.com. The replay webcast will
be available following the presentation and will be archived for
approximately 30 days.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven
approach and drug discovery capabilities to create small molecule
drugs for viral infections and liver diseases. Enanta’s research
and development is currently focused on four disease targets:
Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Non-alcoholic
Steatohepatitis (NASH) and Respiratory Syncytial Virus (RSV).
Enanta has developed novel protease inhibitors and NS5A inhibitors
that are members of the direct-acting-antiviral (DAA) inhibitor
classes designed for use against the hepatitis C virus (HCV).
Enanta’s protease inhibitors, developed through its collaboration
with AbbVie, include paritaprevir, which is contained in AbbVie’s
marketed DAA regimens for HCV, and ABT-493, Enanta’s
next-generation protease inhibitor, which AbbVie is developing in
phase 3 studies in combination with ABT-530, AbbVie’s
next-generation NS5A inhibitor. Enanta has also discovered a
cyclophilin inhibitor, EDP-494, a novel host-targeting mechanism
for HCV, which is now in a phase 1 clinical development, and
EDP-305, an FXR agonist, which Enanta plans to advance into
clinical development for NASH later in 2016. Please visit
www.enanta.com for more information on our programs and
pipeline.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160201005099/en/
Investor Contact:Enanta Pharmaceuticals, Inc.Carol
Miceli, 617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024